文献速递瓣膜病与结构性心脏病

女性经导管与外科主动脉瓣置换对比:RHEIA试验

Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial.
PubMed 文献 · Eur Heart J · 2025-01-01

RHEIA试验将443例严重症状性主动脉瓣狭窄女性随机分至经股动脉球囊扩张瓣TAVI或外科换瓣,主要终点为1年死亡、卒中或再住院复合终点。

要点

  • 女性严重主动脉瓣狭窄患者中,TAVI较外科换瓣降低1年死亡、卒中或再住院复合终点。
  • 1年再住院率TAVI组5.8%低于外科组11.4%,死亡与卒中组件两组数值接近。

核心结论

  • 在严重主动脉瓣狭窄女性中,TAVI组1年死亡、卒中或再住院复合终点发生率低于外科换瓣组。

研究设计与样本

  • RHEIA为随机对照试验,48个欧洲中心纳入443例女性,1:1随机至经股动脉球囊扩张瓣TAVI或外科换瓣,420例按随机方案治疗。
  • 平均年龄73岁,平均预估外科死亡风险(STS评分)2.1%;主要终点为1年死亡、卒中或瓣膜/手术/心衰相关再住院复合终点。
  • 采用非劣效检验(预设界值6%)与优效检验,在按治疗人群中分析。

主要发现

  • 1年主要终点Kaplan-Meier估计事件率:TAVI组8.9%,外科组15.6%。

临床怎么用

  • 对于严重症状性主动脉瓣狭窄女性,TAVI可考虑作为外科换瓣的替代方案,以降低1年死亡、卒中或再住院复合风险。
  • 试验纳入平均外科风险约2.1%的女性人群,临床决策应结合个体风险评估与瓣膜解剖特征。

局限性

  • 原文摘要未报告试验的盲法设计、具体随访时长及亚组分析结果。
  • 原文摘要未报告主要终点组件之外的次要终点或安全性终点详细数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Although women with severe symptomatic aortic stenosis have more complications than men when undergoing surgical valve replacement, they are under-represented in clinical trials. The Randomized researcH in womEn all comers wIth Aortic stenosis (RHEIA) trial investigates the balance of benefits and risks of transcatheter aortic valve implantation (TAVI) vs. surgery in women. METHODS: Women were randomized 1:1 to transfemoral TAVI with a balloon-expandable valve or surgery. The primary composite endpoint was death, stroke, or (valve, procedure or heart failure related) rehospitalization at 1 year. Non-inferiority testing with a pre-specified 6% margin and superiority testing were performed in the as-treated population. RESULTS: At 48 European centres, 443 women underwent randomization, and 420 were treated as randomized. Mean age was 73 years, and the mean estimated surgical risk of death was 2.1% (Society of Thoracic Surgeons risk score). Kaplan-Meier estimates of the primary endpoint event rates at 1 year were 8.9% in the TAVI and 15.6% in the surgery group. This difference of -6.8% with an upper 95% confidence limit of -1.5% demonstrated the non-inferiority of TAVI (P < .001). The two-sided 95% confidence interval of -13.0% to -.5% further resulted in superiority (P = .034). The 1-year incidence of the primary endpoint components was: .9% with TAVI vs. 2.0% with surgery for death from any cause, 3.3% vs. 3.0% for stroke, and 5.8% vs. 11.4% for rehospitalization. CONCLUSIONS: Among women with severe aortic stenosis, the incidence of the composite of death, stroke, or rehospitalization at 1 year was lower with TAVI than with surgery. CLINICALTRIALS.GOV NUMBER: NCT04160130.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Tchetche D, Pibarot P, Bax JJ, et al. Transcatheter vs. surgical aortic valve replacement in women: the RHEIA trial. Eur Heart J. 2025. PMID: 40171878. doi:10.1093/eurheartj/ehaf133

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。